Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.10% | 7.75% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.34% | 29.85% | -- | -- | -- |
| Operating Income | 10.34% | -29.85% | -- | -- | -- |
| Income Before Tax | 165.59% | 138.09% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 165.61% | 138.09% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 165.61% | 138.09% | -- | -- | -- |
| EBIT | 10.34% | -29.85% | -- | -- | -- |
| EBITDA | -157.19% | -- | -- | -- | -- |
| EPS Basic | 243.32% | 397.90% | -- | -- | -- |
| Normalized Basic EPS | 73.67% | -45.12% | -- | -- | -- |
| EPS Diluted | 243.32% | 397.90% | -- | -- | -- |
| Normalized Diluted EPS | 73.67% | -45.12% | -- | -- | -- |
| Average Basic Shares Outstanding | -62.21% | -56.39% | -- | -- | -- |
| Average Diluted Shares Outstanding | -62.21% | -56.39% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |